Stenting for symptomatic vertebral artery stenosis
Open Access
- 19 September 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 89 (12) , 1229-1236
Abstract
Objective: To compare in the Vertebral Artery Ischaemia Stenting Trial (VIST) the risks and benefits of vertebral angioplasty and stenting with best medical treatment (BMT) alone for symptomatic vertebral artery stenosis. Methods: VIST was a prospective, randomized, open-blinded endpoint clinical trial performed in 14 hospitals in the United Kingdom. Participants with symptomatic vertebral stenosis ≥50% were randomly assigned (1:1) to vertebral angioplasty/stenting plus BMT or to BMT alone with randomization stratified by site of stenosis (extracranial vs intracranial). Because of slow recruitment and cessation of funding, recruitment was stopped after 182 participants. Follow-up was a minimum of ≥1 year for each participant. Results: Three patients did not contribute any follow-up data and were excluded, leaving 91 patients in the stent group and 88 in the medical group. Mean follow-up was 3.5 (interquartile range 2.1–4.7) years. Of 61 patients who were stented, stenosis was extracranial in 48 (78.7%) and intracranial in 13 (21.3%). No periprocedural complications occurred with extracranial stenting; 2 strokes occurred during intracranial stenting. The primary endpoint of fatal or nonfatal stroke occurred in 5 patients in the stent group vs 12 in the medical group (hazard ratio 0.40, 95% confidence interval 0.14–1.13, p = 0.08), with an absolute risk reduction of 25 strokes per 1,000 person-years. The hazard ratio for stroke or TIA was 0.50 (p = 0.05). Conclusions: Stenting in extracranial stenosis appears safe with low complication rates. Large phase 3 trials are required to determine whether stenting reduces stroke risk. ISRCTN.com identifier: ISRCTN95212240. Classification of evidence: This study provides Class I evidence that for patients with symptomatic vertebral stenosis, angioplasty with stenting does not reduce the risk of stroke. However, the study lacked the precision to exclude a benefit from stenting.Keywords
This publication has 13 references indexed in Scilit:
- Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?Stroke, 2015
- Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trialThe Lancet Neurology, 2015
- Effect of a Balloon-Expandable Intracranial Stent vs Medical Therapy on Risk of Stroke in Patients With Symptomatic Intracranial StenosisJAMA, 2015
- Posterior circulation ischaemic stroke and transient ischaemic attack: diagnosis, investigation, and secondary preventionThe Lancet Neurology, 2013
- Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosisCochrane Database of Systematic Reviews, 2012
- Stenting versus Aggressive Medical Therapy for Intracranial Arterial StenosisNew England Journal of Medicine, 2011
- Noninvasive Detection of Vertebral Artery StenosisStroke, 2009
- Long-Term Outcome After Angioplasty and Stenting for Symptomatic Vertebral Artery Stenosis Compared With Medical Treatment in the C arotid A nd V ertebral A rtery T ransluminal A ngioplasty S tudy (CAVATAS)Stroke, 2007
- Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: Case series and review of the literatureJournal of Vascular Surgery, 2006
- Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosisThe Lancet, 2003